Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, 6-week, Multicenter, Randomized, Double Blind (Patient and Investigator) or Masked, Placebo Controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 as Adjunctive Therapy in MD

NCT06280235 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT06280235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06280235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, 6-week, Multicenter, Randomized, Double Blind (Patient and Investigator) or Masked, Placebo Controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 as Adjunctive Therapy in MD
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
March 27, 2024
Completion date
March 28, 2025
Enrollment
243 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major